Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Novavax logo — Powering innovation. Protecting health.

Novavax

Powering innovation. Protecting health.

Founded 1987 United States Gaithersburg, United States 970 employees Post-IPO Equity Total: $2.71B Biotechnology, Health Care +1

General Information

Company Name Novavax
Founded Year 1987
Location United States Gaithersburg, United States
Founders / Decision Makers
Team member Team member
Employees 970
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Business Model B2B, B2G, D2C
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Novavax. To contact Novavax, visit novavax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Novavax compare?

A PDF of Novavax and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Novavax soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Novavax

Novavax, founded in 1987, is a proactive leader in the Biotechnology, Health Care, and Pharmaceutical industries. With its headquarters in the United States, the company is driven by the mission of bolstering global health through its pioneering technology, encapsulated by its slogan: "Powering innovation. Protecting health."

With a recent $85.00M Post-IPO Equity investment on 08 August 2023 from SK Bioscience, Novavax demonstrates robust investor confidence and financial stability. This influx of capital signals potential for growth and expansion, allowing the company to further its vision of impacting billions by transforming global health.

For investors and venture capitalists, Novavax represents a dynamic opportunity in a sector poised for vital advancements. The enduring presence since its founding highlights its resilience and capacity to adapt in a constantly evolving industry landscape.

Business keywords: vaccine development, infectious diseases, recombinant technology, genetic engineering, nanoparticle vaccines, Matrix-M adjuvant, COVID-19 vaccine, influenza vaccine, clinical trials, immune response enhancement, neutralizing antibodies, public health, global health innovation, SARS-CoV-2

Services & Products

Vaccine Research and Development
Adjuvant Technology Platform
Scientific Publications
Partnerships with Pharma Companies
Pipeline Management

Target Customers

Healthcare Providers Patients in Disease-Prone Areas Pharmaceutical Companies Investors in Biotechnology Public Health Institutions

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $85.00M 1
SK Bioscience
08 Aug 2023
Post IPO Equity $74.75M -
15 Dec 2022
Post IPO Debt $175.25M -
14 Dec 2022
Grant $1.60B 1
Government of United States of America
07 Jul 2020
Post IPO Equity $200.00M 1
RA Capital Management
RA Capital Management
15 Jun 2020
Grant $384.00M 1
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations
11 May 2020
Grant $4.00M 1
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations
10 Mar 2020
Grant $89.00M 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
29 Sep 2015
Post IPO Equity $94.60M -
13 Sep 2013
Post IPO Equity $5.02M 1
Innovations Kapital
27 Jun 2008

Latest News

View All
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots — Cnbc
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Cnbc Sep 12, 2025
FDA approves new Covid shots with limits on who can get them under RFK Jr. — Cnbc
FDA approves new Covid shots with limits on who can get them under RFK Jr.
Cnbc Aug 27, 2025
FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says — Cnbc
FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says
Cnbc Aug 12, 2025
Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS — Cnbc
Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Cnbc Nov 14, 2024
FDA authorizes Novavax’s updated Covid vaccine, paving way for fall rollout — Cnbc
FDA authorizes Novavax’s updated Covid vaccine, paving way for fall rollout
Cnbc Aug 30, 2024
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial — Cnbc
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Cnbc Jun 10, 2024

Novavax Alternatives & Competitors

View All Alternatives
Novavax vs
KAICO Ltd.
KAICO Ltd. Japan

Changing the World with Silkworms

Series B
10 employees
Biotechnology, Pharmaceutical
Novavax vs
The Duke Human Vaccine Institute
The Duke Human Vaccine Institute United States

Innovation, Collaboration and Excellence

Grant
214 employees
Biotechnology, Health Care
Novavax vs
X-Vax Technology
X-Vax Technology

Pioneering the future of vaccines to conquer mucosal infections and protect millions globally.

Series A
Biotechnology, Health Care
Also compare with: Novavax vs Osivax Osivax Novavax vs SINOVAC BIOTECH LTD. SINOVAC BIOTECH LTD. View all alternatives

FAQ About Novavax

Powering innovation. Protecting health.
Novavax was founded in 1987.
Novavax is headquartered in Gaithersburg, United States.
Novavax operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on vaccine development, infectious diseases, recombinant technology and genetic engineering. Its customers include Healthcare Providers, Patients in Disease-Prone Areas and Pharmaceutical Companies.
Novavax has a B2B, B2G and D2C business model. Its revenue comes from Product Sales and Licensing.
Novavax has approximately 970 employees.
Novavax has completed 10 funding rounds, raising a total of $2.71B. The latest funding stage is Post-IPO Equity.
Novavax offers: Vaccine Research and Development, Adjuvant Technology Platform, Scientific Publications, Partnerships with Pharma Companies, Pipeline Management.
Top alternatives and competitors to Novavax include KAICO Ltd., The Duke Human Vaccine Institute, X-Vax Technology, Rocketvax AG, Providence Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Novavax and KAICO Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Novavax, https://bouncewatch.com/company/novavax, updated 16 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes